Advertisement
News
Advertisement

Clinical Data Demonstrates That LYSTEDA Significantly Reduced Menstrual Blood Loss and Limitations on Social, Leisure and Physical Activities in Women With Cyclic HMB

Wed, 05/19/2010 - 7:37am
Bio-Medicine.Org

SAN FRANCISCO, May 19 /PRNewswire/ -- Five presentations reporting the results of two placebo-controlled clinical trials evaluating Ferring Pharmaceuticals' LYSTEDA™ (tranexamic acid) tablets, a novel, first-in-class, non-hormonal therapy indicated for treatment of women with cyclic heavy menstrual bleeding (HMB), were presented at The American College of Obstetricians and Gynecologists 58th Annual Clinical Meeting in San Francisco, May 15-19, 2010.  It is estimated that up to 22 million women suffer from HMB in the U.S.(1),(2)

(Logo:  http://www.newscom.com/cgi-bin/prnh/20100510/NY01272LOGO )

LYSTEDA oral tablets received approval on November 13, 2009 following a Priority Review by the U.S. Food and Drug Administration (FDA).  Ferring recently signed an agreement with Xanodyne Pharmaceuticals, Inc. that will expand its Women's Health product portfolio with the acquisition of the global rights to LYSTEDA, which the company will initially market in the U.S.

"We are extremely pleased by the substantial clinical evidence supporting LYSTEDA as a new therapy for heavy menstrual bleeding.  LYSTEDA was shown to significantly reduce menstrual blood loss in women suffering from cyclic heavy menstrual bleeding," said Andrea Lukes, MD, lead study investigator, Carolina Women's Research and Wellness Center.  "As a result of taking this new treatment, most women in the trial said t

'/>"/>

SOURCE

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading